Here are three reasons that I think investors ought to buy CSL Limited (ASX:CSL) shares today…
The post 3 reasons I would buy CSL (ASX:CSL) shares today appeared first on Motley Fool Australia. –
If you’re looking to make an investment in the Australian share market, then I think CSL Limited (ASX: CSL) shares would be a great option.
Three key reasons that I rate the company highly are listed below:
Australia’s highest quality business?
The first reason to consider buying CSL is its quality. In fact, I would argue that the biotherapeutics giant is Australia’s highest quality business. It is made up of two businesses – CSL Behring and Seqirus. CSL Behring is a global biotechnology leader which offers the broadest range of quality plasma-derived and recombinant therapies in the industry. Whereas Seqirus is one of the world’s leading vaccines developers with a focus on influenza. It is also supporting the efforts to develop and manufacture a COVID-19 vaccine. Combined, I believe these two businesses have positioned CSL perfectly for growth over the long term.
Although the CSL share price has recovered from its lows, it is still trading some distance from its 52-week high. I think this has left its shares trading at an attractive level for a long-term focused investor. And while the pandemic is having a negative impact on its plasma collections, which are a key ingredient to its immunoglobulin products, I’m optimistic that this will be partly offset by increased demand for seasonal flu vaccines because of the pandemic. This could make now an opportune time to pick up shares.
Research and development pipeline.
Did you know that every year CSL invests approximately 10% to 11% of its sales into research and development (R&D) activities? So, with sales revenue in FY 2020 hitting US$8,797 million, the company is now investing almost US$1 billion each year into its R&D. This high level of investment ensures that the company has some of the most talented scientists in the industry working for it. It also means that its R&D pipeline is filled to the brim with therapies and vaccines that have the potential to generate significant revenues in the future.
The CSL share price has smashed the market over the last 10 years. Due to the three reasons listed above, I’m confident it will do the same again over the next decade.
In light of this, I would class CSL shares as a strong buy.
These stocks could rocket in a Post-COVID world (FREE STOCK REPORT)
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.
*Returns as of 6/8/2020
- ASX 200 rises 1% again, Zip (ASX:Z1P) soars 8%
- ASX 200 up 0.8%: Big four banks higher, CSL rises on vaccine update, Zip rockets
- CSL (ASX:CSL) share price higher on COVID-19 vaccine update
- 3 ASX shares to buy in a US election selloff
- Federal Budget: What it means for the CSL (ASX:CSL) share price
James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.